Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large-cell lymphoma

Experimental Hematology

Volumn 31, Issue 3, 2003, Pages 226-233

  Hübinger, Gabriele ^a,d   Wehnes, Engelbert ^b   Xue, Liquan ^c   Morris, Stephan W ^c   Maurer, Ulrich ^a  

^a UNIVERSITY OF ULM   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d Department of Biology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; DNA; NUCLEOPLASMIN; RIBOZYME; RNA;

ANAPLASTIC CARCINOMA; ARTICLE; CATALYSIS; CHIMERA; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LARGE CELL LYMPHOMA; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 2342540711     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)01084-6     Document Type: Article

References (41)

1. Morris S.W., Kirstein M.N., Valentine M.B.et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 263:1994;1281-1284.
2. Sarris A.H., Luthra R., Papadimitracopoulou V.et al. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Ann Oncol. 8(Suppl 2):1997;59-63.
3. + anaplastic large cell lymphoma. a review of its histopathologic, genetic, and clinical features Blood. 96:2000;3681-3695.
4. + lymphomas. A distinct molecular genetic subtype of non-Hodgkin's lymphoma Br J Haematol. 113:2001;275-295.
5. Chan P.K., Chan F.Y., Morris S.W., Xie Z. Isolation and characterization of the human nucleophosmin/B23 (NPM) gene. identification of the YY1 binding site at the 5′ enhancer region Nucleic Acids Res. 25:1997;1225-1232.
6. Pulford K., Lamant L., Morris S.W.et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 89:1997;1394-1404.
7. Morris S.W., Naeve C., Mathew P.et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase. Oncogene. 14:1997;2175-2188.
8. Bischof D., Pulford K., Mason D.Y., Morris S.W. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 17:1997;2312-2325.
9. Bai R.Y., Dieter P., Peschel C., Morris S.W., Duyster J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity. Mol Cell Biol. 18:1998;6951-6961.
10. Hübinger G., Scheffrahn I., Muller E.et al. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. Exp Hematol. 27:1999;1796-1805.
11. Slupianek A., Nieborowska-Skorska M., Hoser G.et al. Role of PI-3K-AKT pathway in NPM/ALK-mediated lymphomagenesis. Cancer Res. 61:2001;2194-2199.
12. Bai R.Y., Ouyang T., Miething C., Morris S.W., Peschel C., Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 96:2000;4319-4327.
13. Fujimoto J., Shiota M., Iwahara T.et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A. 93:1996;4181-4186.
14. Zamo A., Chiarle R., Piva R.et al. 2002) Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 21:2002;1038-1047.
15. Drexler H.G., Gignac S.M., von Wasielewski R., Werner M., Dirks W.G. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 14:2000;1533-1559.
16. ten Berge R.L., Oudejans J.J., Ossenkoppele G.J.et al. ALK expression in extranodal anaplastic large cell lymphoma favors systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 53:2000;445-450.
17. Gascoyne R.D., Aoun P., Wu D.et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 93:1999;3913-3921.
18. Leoncini L., Megha T., Lazzi S.et al. Cellular kinetic differences between Hodgkin's and anaplastic large cell lymphomas. relation to the expression of p34cdc2 and cyclin B-1 Int J Cancer. 77:1998;408-414.
19. Kuefer M.U., Look A.T., Pulford K.et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood. 90:1997;2901-2910.
20. Cech T.R., Zaug A.J., Grabowski P.J. In vitro splicing of the ribosomal RNA precursor of Tetrahymena. involvement of a guanosine nucleotide in the excision of the intervening sequence Cell. 27:1981;487-496.
21. Uhlenbeck O.C. A small catalytic oligoribonucleotide. Nature. 328:1987;596-600.
22. Leopold L.H., Shore S.K., Newkirk T.A., Reddy R.M., Reddy E.P. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood. 85:1995;2162-2170.
23. Wiechen K., Zimmer C., Dietel M. Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein. Cancer Gene Ther. 5:1998;45-51.
24. Funato T., Ishii T., Kambe M., Scanlon K.J., Sasaki T. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells. Cancer Gene Ther. 7:2000;495-500.
25. Cheng J., Luo J., Zhang X.et al. Inhibition of cell proliferation in HCC-9204 hepatoma cells by a c-myc-specific ribozyme. Cancer Gene Ther. 7:2000;407-412.
26. Kamochi J., Tokunaga T., Morino F.et al. Ribozyme-mediated suppression of vascular endothelial growth factor gene expression enhances matrix metalloproteinase 1 expression in a human hepatocellular carcinoma cell line. Int J Oncol. 21:2002;81-84.
27. Hübinger G., Schmid M., Linortner S., Manegold A., Bergmann L., Maurer U. Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells. Exp Hematol. 29:2002;1226-1235.
28. cip1/ waf1 in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene. 20:2001;590-598.
29. Birikh K.R., Heaton P.A., Eckstein F. The structure, function and application of the hammerhead ribozyme. Eur J Biochem. 245:1997;1-16.
30. James H.A., Gibson I. The therapeutic potential of ribozymes. Blood. 91:1998;371-382.
31. Okuda M., Horn H.F., Tarapore P.et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 103:2000;127-140.
32. + lymphoma. Clinico-pathological findings and outcome Blood. 93:1999;2697-2706.
33. Hernandez L., Pinyol M., Hernandez S.et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood. 94:1999;3265-3268.
34. Lawrence B., Perez-Atayde A., Hibbard M.K.et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 157:2000;377-384.
35. Colleoni G.W., Bridge J.A., Garicochea B., Liu J., Filippa D.A., Ladanyi M. Atic-alk. A novel variant alk gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35) Am J Pathol. 156:2000;781-789.
36. Ma Z., Cools J., Marynen P.et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood. 95:2000;2144-2149.
37. + anaplastic large cell lymphoma. Cancer Res. 60:2000;793-798.
38. + lymphoma. 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like) Blood. 95:2000;3204-3207.
39. Salgia R., Quackenbush E., Lin J.et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1α Blood. 94:1999;4233-4246.
40. Dhut S., Chaplin T., Young B.D. BCR-ABL and BCR proteins. biochemical characterization and localization Leukemia. 4:1990;745-750.
41. Spiller D.G., Giles R.V., Broughton C.M.et al. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses. Antisense Nucleic Acid Drug Dev. 8:1998;281-293.